HAG预激方案治疗低增生性急性髓细胞白血病临床研究  

Clinical Research of HAG Priming Induction Regimen for the Treatment of Low Proliferative Acute Myeloid Leukemia

作　　者：韩乔燕[1] 孙淼[1] 王苇[1] 刘春华[1] 吴玲玉[1] 

机构地区：[1]靖江市人民医院,江苏靖江214500

出　　处：《世界中西医结合杂志》2011年第3期222-224,共3页World Journal of Integrated Traditional and Western Medicine

摘　　要：目的探讨HAG预激方案对低增生性急性髓细胞白血病患者的临床疗效及不良反应。方法对28例低增生性急性髓细胞白血病(AML)患者采用HAG预激方案化疗,监测临床症状、体征、血常规及骨髓细胞形态学检查。结果 28例患者中第1个疗程完全缓解15例,第2个疗程完全缓解5例,3例部分缓解,4例未缓解,1例治疗中死于脑出血;1个疗程完全缓解率53.6%,总疗程完全缓解率71.4%,总有效率82.1%。外周血WBC低于1.0×109/L的中位时间为7.2(1～16)d。结论 HAG预激方案治疗低增生性AML近期疗效显著,不良反应轻,患者耐受性较好,且有利于减轻患者的经济负担,有一定的临床推广价值。Objective To explore the clinical efficacy and adverse reaction of HAG priming induction regimen for the treatment of low proliferative acute myeloid leukemia（AML）.Methods 50 cases of low proliferative AML were treated with chemotherapy of HAG priming induction regimen.The clinical symptoms,physical signs,blood routine and morphologic examination of bone marrow and cells were monitored.Results Of 28 cases,15 cases were released completely after the 1st session of treatment,5 cases were released completed after the 2nd session of treatment,3 cases were released partially,4 cases were not released and 1 case died from cerebral hemorrhage.The complete release rate after one session of treatment was 53.6%,the complete release rate after the total sessions of treatment was 71.4% and the total effective rate was 82.1%.The median time of the peripheral blood WBC less than 1.0 × 109/L was 7.2（1~16）days.Conclusion HAG priming induction regimen achieves significant short-term efficacy on low proliferative AML,being advantageous in mild adverse reaction,good tolerance in patients and reducing the economic burden of patients.Hence,this therapy is valuable to a certain extent in clinical promotion.

关 键 词：预激方案 急性髓细胞性白血病 粒细胞集落刺激因子 

分 类 号：R733.71[医药卫生—肿瘤]